-transparent.png){kind=logo}
We have recently reported an increase in HLA-DR1 in 52 patients with thyroid epithelial cancer from Eastern Hungary (Juhasz et al., 1986). We have now investigated the association of IgG heavy chain markers (Gm) in 50 patients with this disease and explored possible interaction between Gm and HLA in modifying the risk for thyroid cancer. No Gm phenotype showed significant increases in the patients compared to 168 local controls. When both Gm and HLA, however, were considered, a marked heterogeneity in risk was noted. The odds ratio for DR1+fb+ homozygotes was 37.5, for DR1+fb- individuals 6.0 and for DR1-fb+ individuals 2.6 (DR1-fb- = 1.0). Thus Gm and HLA interact to enhance greatly the risk of thyroid cancer.
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
September 1981,
Immunology today,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
March 1985,
Clinical rheumatology,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
October 1980,
Clinical and experimental immunology,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
July 1986,
American journal of human genetics,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
October 1982,
Journal of immunogenetics,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
December 1983,
The Tohoku journal of experimental medicine,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
March 1993,
Molecular immunology,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
June 1983,
Clinical and experimental immunology,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
January 1989,
Experimental and clinical immunogenetics,
F Juhasz, and
G Balazs, and
L Kozma, and
E Kraszits, and
V Stenszky, and
N R Farid
February 1981,
The New England journal of medicine,
